ARTICLE | Financial News
Celgene products drive BeiGene 4Q revenue gains
February 28, 2019 12:50 AM UTC
BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Wednesday with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG).
BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide and Vidaza azacitidine from Celgene, which BeiGene received in return for licensing its PD-1 inhibitor tislelizumab (BGB-A317) to Celgene under a July 2017 deal (see “Thinking Globally, Acting Locally”)...